Zydus Wellness News and Updates

Name: Latest research reports of Zydus Wellness Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Zydus Wellness Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news on Zydus Wellness from all sources in a single place.

Zydus Wellness Ltd.

12 Jan 2026

439.70

-0.92%

Zydus can sell anti-cancer drug Nivolumab biosimilar in India, says Delhi high court

livemint

The court directed Zydus to maintain detailed and audited records of its sales during this period so that the innovator can be compensated in case it ultimately succeeds in the patent infringement suit.

Zydus Wellness Ltd. is trading below its 50 day SMA of 440.7

Zydus Wellness Ltd.

31 Dec 2025

439.70

-0.92%

Zydus Wellness zooms 10% in trade; Motilal Oswal initiates 'Buy'; check TP

Business Standard

Motilal Oswal Financial Services has initiated coverage on Zydus Wellness with 'Buy' for a target of 575, which implies an upside of 25.8 per cent from current levels

Zydus Wellness Ltd. has an average target of 562.50 from 6 brokers.

Zydus Wellness Has Attractive Risk-Reward Profile, Says Motilal Oswal On 'Buy' Initiation Check Details

NDTV Profit | 31 Dec 2025

Zydus Wellness Ltd.

31 Dec 2025

439.70

-0.92%

Scaling up the wellness brand equity

Buy: Zydus Wellness Ltd.

Motilal Oswal

Zydus Wellness is a diversified health and nutrition company (~INR40bn revenue) with leadership in several consumer wellness categories. The company’s core portfolio consists of sugar substitutes (Sugar Free), glucose powders (Glucon-D), skincare (Everyuth), functional foods (Nutralite), prickly-heat powder (Nycil), and nutritional beverages (Complan).

Zydus Wellness Ltd. has an average target of 562.50 from 6 brokers.

Zydus Wellness Ltd.

19 Dec 2025

439.70

-0.92%

Zydus Wellness rallied on the Comfort Click deal. Has the excitement faded?

livemint

After acquiring UK-based Comfort Click for 2,380 crore, Zydus' stock surged. The move expands its global wellness footprint, but near-term profitability pressures remain.

Zydus Wellness Ltd. is trading above its 200 day SMA of 419.4

Zydus Wellness Ltd.

15 Dec 2025

439.70

-0.92%

Zydus Life's US arm gets FDA nod for Menkes disease drug resubmission

Business Standard

The drug, CUTX-101, is intended for the treatment of Menkes disease, a rare X-linked recessive genetic disorder affecting male children

Zydus Wellness Ltd. is trading below its 50 day SMA of 440.7

Zydus Wellness Ltd.

10 Dec 2025

439.70

-0.92%

Zydus Lifesciences introduces biosimilar for cancer patients' bone health

Business Standard

Zydus Lifesciences on Wednesday said it has launched a biosimilar for the treatment of osteoporosis and the prevention of skeletal complications in cancer patients. The company has launched Zyrifa, a Denosumab biosimilar. Denosumab is a monoclonal antibody with several indications related to bone health, primarily in the treatment of osteoporosis and the prevention of skeletal complications in cancer patients. This will provide access and treat patients with bone metastases due to breast, prostate, lung, myeloma, kidney, thyroid, head & neck, and other solid tumours, the Ahmedabad-based drug firm said in a regulatory filing. Metastases, is when the cancer spreads to the bones and other organs in the body indicating an advanced stage of cancer. The company said it has priced 'Zyrifa' at MRP of Rs 12,495. Sharvil P Patel, Managing Director, Zydus Lifesciences Ltd said that with Denosumab 120 mg SC, the company aims to bring access, affordability of medication in cancer patients...

Zydus Wellness Ltd. has an average target of 562.50 from 6 brokers.

Zydus Lifesciences shares rise 2% on expanding its biosimilar portfolio

Business Standard | 10 Dec 2025 1 more

Zydus Wellness Ltd.

26 Nov 2025

439.70

-0.92%

Zydus Lifesciences, RK Pharma sign deal for licensing, commercialisation

Business Standard

Zydus Lifesciences Ltd on Wednesday said it has entered into an exclusive licensing and commercialisation agreement with RK Pharma Inc of the US for a new sterile injectable oncology supportive care product for the US market. Under the terms of this agreement, RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA (new drug application) submission and commercialisation of the product in the US, the company said in a regulatory filing. The product is expected to be filed in 2026 and will provide a formulation that is intended to provide reduced dosing error and enhanced compliance of healthcare professionals, it added. "This partnership reinforces our commitment to delivering high-quality, affordable medicines and improving patient care," Zydus Lifesciences Managing Director Sharvil Patel said. RK Pharma Founder and Executive Chairman Ravishanker Kovi said, "Our collaboration with Zydus, a company with robust regulatory expertise and

Motilal Oswal released a Buy report for Zydus Wellness Ltd. with a price target of 575.0 on 31 Dec, 2025.

Zydus Lifesciences shares rise after USFDA nod, RK Pharma licensing deal

Business Standard | 26 Nov 2025

Zydus Wellness Ltd.

18 Nov 2025, 04:39PM

439.70

-0.92%

Zydus partners with SIG to launch single-serve spouted pouches for cough medicine

Business Line

The new format offers precise dosing, better hygiene, and reduced wastage using SIG's advanced filling technology.

Zydus Wellness Ltd. has an average target of 562.50 from 6 brokers.

Zydus Wellness Ltd.

13 Nov 2025

439.70

-0.92%

Zydus' Amplitude receives CE mark for its robotic surgical system Andy'

Business Line

This approval means the product complies with European standards for safety, performance, and quality, according to a statement

Motilal Oswal released a Buy report for Zydus Wellness Ltd. with a price target of 575.0 on 31 Dec, 2025.

Zydus Wellness Ltd.

11 Nov 2025

439.70

-0.92%

Zydus Gets Chinese Health Regulator Nod For Generic Anxiety Drug

NDTV Profit

Venlafaxine ER capsules are indicated for the treatment of major depressive disorder, generalised anxiety disorder, social anxiety disorder and panic disorder.